Using Heat Shock Proteins to Improve the Therapeutic Benefit of a Non-vaccine Treatment Modality

The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an alpha-2-macroglobulin (alpha2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an alpha2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or alpha2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.

Patents:
US 20,090,208,524

Inventor(s): SRIVASTAVA PRAMOD K [US]; LI ZIHAI [US]

Type of Offer: Licensing



« More Medical Patents

---